# X I . News Releases

Major news releases during October 2009 - March 2010 are as below.

Please refer to our web site for details (http://www.takeda.com/).

| Date | Summary |
|---|---|
| 1-Oct-09 | Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors |
| 1-Oct-09 | Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe |
| 19-Oct-09 | Approval of an Additional Indication of BASEN®; Prevention of Onset of Type 2 Diabetes in Patients with Impaired Glucose Tolerance |
| 2-Nov-09 | Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity |
| 18-Nov-09 | TAK-438 Enters Phase 2 Clinical Trials for the Treatment of Reflux Esophagitis |
| 25-Nov-09 | Takeda Submitted an Application for an Additional Indication for Takepron® Capsules 15 and Takepron® OD Tablet 15 in Japan for new indications regarding Prevention of NSAIDs-Associated Gastric Ulcer/Duodenal Ulcer |
| 2-Dec-09 | Takeda to Continue Strategic Expansion with Operations in Brazil |
| 14-Dec-09 | TAK-085 Entered into Phase 3 Clinical Programs for Treatment of Hypertriglyceridemia in Japan |
| 15-Dec-09 | Takeda and Pfizer to Co-Promote Takeda's Actos® (pioglitazone HCl) for the Treatment of Type 2 Diabetes in China |
| 15-Dec-09 | Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35) |
| 18-Jan-10 | Approval of Actos® Orally Disintegrating Tablets in Japan |
| 1-Feb-10 | First Treatment to Improve Survival in 20 Years Now Available for Patients with Osteosarcoma (Bone Cancer) |
| 18-Feb-10 | Hematide™ Entered into The Phase 3 Clinical Program to Treat Anemia in Chronic Renal Failure Patients in Japan |
| 23-Feb-10 | Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity |
| 3-Mar-10 | Lundbeck and Takeda finalise plans to initiate phase 3 pivotal clinical trials with Lu AA21004 and Lu AA24530 |
| 5-Mar-10 | KAPIDEX™ (dexlansoprazole) Renamed DEXILANT™ in U.S. to Avoid Name Confusion |
| 16-Mar-10 | A Once-Monthly Formulation of Risedronate Sodium Hydrate for the Treatment of Osteoporosis Entered Into Phase 3 Clinical Programs in Japan |
| 19-Mar-10 | Takeda Announces Withdrawal of Marketing Authorization Application for a Prolonged-Release Formulation of Competact® and discontinuation of its development in the EU |
| 25-Mar-10 | Takeda Submits Application in Japan for Additional Indications of Alogliptin for Combination Therapy with Sulfonylurea and Combination Therapy with Biguanide |